These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30851173)

  • 41. Analyzing predictors of graft survival in patients undergoing liver transplantation with donors aged 70 years and over.
    Caso-Maestro O; Jiménez-Romero C; Justo-Alonso I; Calvo-Pulido J; Lora-Pablos D; Marcacuzco-Quinto A; Cambra-Molero F; García-Sesma A; Pérez-Flecha M; Muñoz-Arce C; Loinaz-Segurola C; Manrique-Municio A
    World J Gastroenterol; 2018 Dec; 24(47):5391-5402. PubMed ID: 30598583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Joint Assessment of Donor and Recipient hTERT Gene Polymorphism Provides Additional Information for Early Kidney Transplantation Outcomes.
    Kłoda K; Mierzecki A; Domański L; Borowiecka E; Safranow K; Ciechanowicz A; Ciechanowski K
    Med Sci Monit; 2017 Apr; 23():1812-1818. PubMed ID: 28410362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.
    Botha JF; Thompson E; Gilroy R; Grant WJ; Mukherjee S; Lyden ER; Fox IJ; Sudan DL; Shaw BW; Langnas AN
    Liver Int; 2007 Aug; 27(6):758-63. PubMed ID: 17617118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.
    Khapra AP; Agarwal K; Fiel MI; Kontorinis N; Hossain S; Emre S; Schiano TD
    Liver Transpl; 2006 Oct; 12(10):1496-503. PubMed ID: 16964597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index.
    Benlloch S; Berenguer M; Prieto M; Rayón JM; Aguilera V; Berenguer J
    Liver Transpl; 2005 Apr; 11(4):456-62. PubMed ID: 15776403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M; Aguilera V; Prieto M; Carrasco D; Rayón M; San Juan F; Landaverde C; Mir J; Berenguer J
    Liver Transpl; 2003 Nov; 9(11):1152-8. PubMed ID: 14586875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
    Ackefors M; Nyström J; Wernerson A; Gjertsen H; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Nov; 20(11):770-8. PubMed ID: 24168256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.
    Aguilera V; Berenguer M; Rubín A; San-Juan F; Rayón JM; Prieto M; Mir J
    Liver Transpl; 2009 Jan; 15(1):79-87. PubMed ID: 19109849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus.
    Taner CB; Bulatao IG; Keaveny AP; Willingham DL; Pungpapong S; Perry DK; Rosser BG; Harnois DM; Aranda-Michel J; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):641-9. PubMed ID: 21618684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
    Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
    J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation.
    Shaked O; Demetris J; Levitsky J; Feng S; Loza BL; Punch J; Reyes J; Klintmalm G; Jackson W; DesMarais M; Sayre P; Shaked A; Reddy KR
    Transplantation; 2022 Jan; 106(1):106-116. PubMed ID: 33982909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.
    Nagai S; Yoshida A; Kohno K; Altshuler D; Nakamura M; Brown KA; Abouljoud MS; Moonka D
    Hepatology; 2014 Jan; 59(1):35-45. PubMed ID: 23728831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation.
    Carrión JA; Torres F; Crespo G; Miquel R; García-Valdecasas JC; Navasa M; Forns X
    Hepatology; 2010 Jan; 51(1):23-34. PubMed ID: 19839063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center.
    Walter T; Dumortier J; Guillaud O; Hervieu V; Scoazec JY; Boillot O
    Liver Transpl; 2007 Feb; 13(2):294-301. PubMed ID: 17256784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Elderly Allografts in Liver Transplantation.
    Paterno F; Wima K; Hoehn RS; Cuffy MC; Diwan TS; Woodle SE; Abbott DE; Shah SA
    Transplantation; 2016 Jan; 100(1):153-8. PubMed ID: 26154390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Domino versus deceased donor liver transplantation: association with early graft function and perioperative bleeding.
    Bispo M; Marcelino P; Marques HP; Martins A; Perdigoto R; Aguiar MJ; Mourão L; Barroso E
    Liver Transpl; 2011 Mar; 17(3):270-8. PubMed ID: 21384509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
    Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
    Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.